HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Poland Kick Starts 2019 With Three Rx-To-OTC Switches

Executive Summary

Clotrimazole, pyrantel, and ciclopirox olamine have been switched from prescription-to-OTC status by Poland's national drug regulator.

You may also be interested in...



Bayer's Canesten Switched From Rx-To-OTC Status In Poland

Poland's drug regulator, URPL, has switched Bayer's Canesten vaginal yeast infection treatment from prescription-to-OTC status. It is the regulator's fourth switch in 2019 alone.

FDA Has Model Drug Facts Labels For OTC Naloxone, Wants Switch Proposals

Development of the model DFLs was a first for agency, reflecting alarm over public health crisis of overdoses from opioid abuse, which reached nearly 48,000 in 2017. The project was "part of our broader commitment to addressing the opioid crisis" and should help sponsors with potential naloxone OTC switch NDAs, says Commissioner Scott Gottlieb.

Polish Consumers Finding It Harder To Access OTC Drugs

Trend of pharmacy closures in 2018 threatens Polish consumers' access to consumer health products, insists local OTC association PASMI. Over 90% of OTC sales in Poland currently go through pharmacies.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1122434

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel